Proteins are the main targets of most drugs; however, system-wide methods to monitor
protein activity and function are still underused in drug discovery. Novel biochemical …

Chronic (continuous, non-interrupted) hypoxia and cycling (intermittent, transient) hypoxia
are two types of hypoxia occurring in malignant tumors. They are both associated with the …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Protein aggregation is the main hallmark of neurodegenerative diseases. Many proteins
found in pathological inclusions are known to undergo liquid-liquid phase separation, a …

Proteolysis-targeting chimeras (PROTACs) are an emerging drug modality that may offer
new opportunities to circumvent some of the limitations associated with traditional small …

The host response to viral infection includes the induction of type I interferons and the
subsequent upregulation of hundreds of interferon-stimulated genes. Ubiquitin-like protein …

As the endpoint for the ubiquitin-proteasome system, the 26S proteasome is the principal
proteolytic machine responsible for regulated protein degradation in eukaryotic cells. The …

More than a decade after a Nobel Prize was awarded for the discovery of the ubiquitin–
proteasome system and clinical approval of proteasome and ubiquitin E3 ligase inhibitors …

Tumor suppressor genes cooperate with each other in tumors. Three important tumor
suppressor proteins, retinoblastoma (Rb), p53, phosphatase, and tensin homolog deleted …

Ubiquitin signaling is a conserved, widespread, and dynamic process in which protein
substrates are rapidly modified by ubiquitin to impact protein activity, localization, or stability …